ResearcherQingdao UniversityActive in the last 2 years

Xiaoya Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9254-638X; OpenAlex author ID A5063764956. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 13

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory facto… Co-author DOI 10.1038/s41392-025-02562-8 ↗
Risk Stratification and Prognosis Determination Based on Protein Lysine Crotonylation in Patients with Resected Pancreatic Cancer: A Multicenter Study. Co-author DOI 10.1158/1078-0432.ccr-24-4300 ↗
A population-based nomogram to individualize treatment modality for pancreatic cancer patients underlying surgery. Co-author DOI 10.1038/s41598-023-31292-6 ↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

He Ren · 2 shared papers, 2025–2026 · strength 0.44
- Paper Risk Stratification and Prognosis Determination Based on Protein Lysine Crotonylation in Patients with Resected Pancrea… DOI 10.1158/1078-0432.ccr-24-4300 ↗
- Paper Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via t… DOI 10.1038/s41392-025-02562-8 ↗
Feng Wei · 1 shared paper, 2025 · strength 0.26
- Paper Risk Stratification and Prognosis Determination Based on Protein Lysine Crotonylation in Patients with Resected Pancrea… DOI 10.1158/1078-0432.ccr-24-4300 ↗
Tiansuo Zhao · 1 shared paper, 2025 · strength 0.26
- Paper Risk Stratification and Prognosis Determination Based on Protein Lysine Crotonylation in Patients with Resected Pancrea… DOI 10.1158/1078-0432.ccr-24-4300 ↗
Lianjing Cao · 1 shared paper, 2025 · strength 0.26
- Paper Risk Stratification and Prognosis Determination Based on Protein Lysine Crotonylation in Patients with Resected Pancrea… DOI 10.1158/1078-0432.ccr-24-4300 ↗
Huan Zhang · 1 shared paper, 2026 · strength 0.19
- Paper Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via t… DOI 10.1038/s41392-025-02562-8 ↗
Chao Gao · 1 shared paper, 2026 · strength 0.19
- Paper Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via t… DOI 10.1038/s41392-025-02562-8 ↗
Qian Yu · 1 shared paper, 2026 · strength 0.19
- Paper Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via t… DOI 10.1038/s41392-025-02562-8 ↗
Ruining Gong · 1 shared paper, 2026 · strength 0.19
- Paper Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via t… DOI 10.1038/s41392-025-02562-8 ↗
Shanglong Liu · 1 shared paper, 2026 · strength 0.19
- Paper Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via t… DOI 10.1038/s41392-025-02562-8 ↗
Qinghui Niu · 1 shared paper, 2026 · strength 0.19
- Paper Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via t… DOI 10.1038/s41392-025-02562-8 ↗
Ashok Kumar Saluja · 1 shared paper, 2026 · strength 0.19
- Paper Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via t… DOI 10.1038/s41392-025-02562-8 ↗
Jieer Ying · 1 shared paper, 2026 · strength 0.19
- Paper Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via t… DOI 10.1038/s41392-025-02562-8 ↗
Wei Bai · 1 shared paper, 2023 · strength 0.18
- Paper A population-based nomogram to individualize treatment modality for pancreatic cancer patients underlying surgery. DOI 10.1038/s41598-023-31292-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.